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ABSTRACT 
Aims: Research on second-generation antipsychotic 
drugs (SGAs) has experienced great development in 
last decades. We did a bibliometric study on the sci- 
entific publications on SGAs in Japan. Methods: 
With the EMBASE and MEDLINE databases, we 
chose papers published from Japan with SGA des- 
criptors. Price’s law and Bradford’s law has been 
used as bibliometric indicators for quantitating pro- 
duction and dispersion, respectively, of published 
papers on SGAs. We also calculated the participation 
index of different countries, and correlated those 
bibliometric data with some social and health data 
from Japan (such as total per capita expenditure on 
health and gross domestic expenditure on research 
and development). Results: A sum of 669 original 
documents were published from Japan from 1982 to 
2011. Those results fulfilled Price’s law, with scien- 
tific production on SGAs showing exponential growth 
(correlation coefficient r = 0.9261, as against an r = 
0.8709 after linear adjustment). The most studied 
SGAs in Japan were risperidone (n = 192), aripi- 
prazole (n = 109), and olanzapine (n = 106). Division 
of documents into Bradford zones yielded a nucleus 
occupied exclusively by the Progress in Neuro-Psy- 
chopharmacology and Biological Psychiatry (49 ar- 
ticles). Those publications were in 157 different jour- 
nals. Seven of the first 10 frequently used journals 
had an impact factor of being greater than 3. Conclu- 
sions: The SGA publications in Japan have been 
through exponential growth over the studied period, 
without evidence of reaching a saturation point. 
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1. INTRODUCTION 
The main pillars for treating schizophrenia during the 
last 60 years have been antipsychotic drugs, after the cli- 
nical introduction of chlorpromazine [1]. The first drugs, 
called first-generation (classical or typical) antipsychotic 
drugs (FGAs), showed a great efficacy at reducing posi- 
tive symptoms (hallucinations, delusion, etc.) of schizo- 
phrenia. But their main limitations are extrapyramidal 
symptoms (EPS). After the re-introduction in the United 
States of clozapine, an antipsychotic drug marketed in 
the 1960s, later withdrawn due to its druginduced agra- 
nulocytosis [2], the research expectations changed dra- 
matically. Apart from causing few EPS, this agent show- 
ed efficacy in both positive and negative symptoms as 
well as in patients who are refractory to treatment with 
other FGAs [3]. Clozapine opened the door to the so- 
called second-generation (atypical) antipsychotic drugs 
(SGAs) [4] with risperidone’s introduction in 1993.  
The advances achieved from antipsychotic drugs in the 
past 30 years have been incredibly important, with the 
advent of many SGAs as shown in Table 1. The Japa- 
nese pharmaceutical companies (Dainippon Sumitomo 
Pharma, Otsuka Pharmaceutical, Fujisawa Pharmaceuti- 
cal, etc.) have played relevant roles. These SGAs have 
notably improved the quality of life of psychotic patients 
and have contributed to weakening the stigmatization [5]. *The authors declare no potential conflict of interest, including finan-
cial support, for the current study. 
#Corresponding author. 
In the US, SGAs were initially introduced in 1993, and 
were later also licensed for treating bipolar disorder in  
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Table 1. Clinical development of second-generation antipsy- 
chotic drugs. 
 Company Launch 
Clozapine Wander Laboratories 1972* Switzerland
Zotepine Fujisawa 1982** Japan 
Amisulpride Synthelabo 1986 Portugal
Risperidone Johnson & Johnson 1993 UK/Canada
Sertindole Abbott Laboratories 1996*** UK 
Olanzapine Eli Lilly 1996 USA/UK
Quetiapine AstraZeneca 1997 USA/UK
Ziprasidone Pfizer 2001 USA 
Perospirone Dainippon Sumitomo Pharma 2001 Japan 
Aripiprazole Otsuka/Bristol-Myers Squibb 2002 USA 
Paliperidone Janssen Pharmaceutica 2007 USA 
Blonanserin Dainippon Sumitomo Pharma 2008 Japan 
Asenapine Schering-Plough 2009 USA 
Iloperidone Novartis AG 2009 USA 
Lurasidone Dainippon Sumitomo Pharma 2011 USA 
*Reintroduced in 1990 in USA and UK after being withdrawn from the mar- 
ket in 1975; **Commercialized by Astellas in Germany in 1990; ***Market- 
ing authorization was suspended by the European Medicines Agency (EMA) 
in 1998 and the drug was withdrawn from the market. In 2002, based on 
new data, the EMA suggested that sertindole could be reintroduced for 
restricted use, and with extensive ECG monitoring requirement. 
 
2003. SGA research has equally advanced considerably 
in Japan although only olanzapine and aripiprazole were- 
first approved in 2012 for treating bipolar disorder there. 
This development in Japan has caused a considerable 
increase in the amount of SGA scientific papers.  
Japan has a great tradition in the care of patients with 
schizophrenia [6]. Japan has the biggest number of psy- 
chiatric beds in the world (with 1600 psychiatric hospi- 
tals). In 1980, more than 300,000 mentally ill stayed at 
psychiatric hospitals in Japan; out of them, more than 
100,000 patients had stayed over 10 years [6]. About 
80% of them were diagnosed as schizophrenia [6]. In ad- 
dition, political, social and economic conditions of Japan 
have greatly influenced the development of psychiatry in 
Japan during last three decades. 
With bibliometric studies, our group has studied the 
evolution of scientific literature in psychiatry by specific 
research groups, on different psychiatric disorders, on 
aspects related to the discipline, and on specific thera- 
peutic tools in psychopharmacology [7-11]. Here, we 
specifically did this bibliometric study on SGA publica- 
tions in Japan. 
2. METHODS 
Due to space limitation, we just stated key concepts of 
methods briefly here. Readers should refer to other arti- 
cles [7-11] for more information in methodology in this 
study.  
In this study, we did not seek the study approval at in- 
stitution’s ethics committee for clinical investigation be- 
cause all the data used in this study were based on sec- 
ondary published materials. We did not do any direct 
experiments on human subjects, therefore, it conforms to 
the provisions of the Declaration of Helsinki (as revised 
in Edinburgh 2000). 
2.1. Data Sources 
The databases used in this bibliometric study were 
MEDLINE (Index Medicus, US National Library of Me- 
dicine, Bethesda, Maryland, USA) and Excerpta Medica 
(Elsevier Science Publishers, Amsterdam, the Nether- 
lands). Both are in EMBASE Biomedical Answer web 
(Elsevier B.V.). 
With remote downloading techniques, we chose all 
1982-2011 published documents, containing, in the au- 
thor’s address (AD) section the descriptor Japan, and in 
the title (TI) section, the descriptors atypic* (atypical) 
antipsychotic* (antipsychotical), second-generation an- 
tipsychotic* (antipsychotical), clozapine, risperidone, 
olanzapine, ziprasidone, quetiapine, sertindole, aripip-
razole, paliperidone, amisulpride, zotepine, asenapine, 
iloperidone, lurasidone, perospirone and blonanserin. 
We included all the original articles, brief articles, re- 
views, editorials, letters-to-the-editor, etc., and all dupli-
cated papers were omitted. 
With manual coding after studying the title and/or ab- 
stracts of the articles, we divided those papers into four 
groups: “experimental pharmacology”, “clinical effica- 
cy”, “tolerance and/or safety” and “not specified group”.  
2.2. Bibliometric Indicators 
2.2.1. Price’s Law 
Price’s law [12] reflects a fundamental aspect of scien- 
tific production, which is its exponential growth. To as- 
sess whether the growth of scientific production in SGAs 
on Japan follows Price’s law of exponential growth, we 
made a linear adjustment of the data obtained, according 
to the equation y = 2.4684x – 16.042, and another ad- 
justment to an exponential curve, according to the equa- 
tion y = 1.534 e0.1313x. 
2.2.2. Bradford’s Law 
To show the dispersion of the scientific literature in a 
particular discipline, Bradford proposed a model of con- 
centric zones of productivity (Bradford zones) with de- 
creasing density of information [13]. Each zone would 
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the period 1982-2011. Its health data were obtained from  contain a similar number of documents, but the number 
of journals in which these are published would increase 
on passing from one zone to another. This model permits 
identification of the journals most widely used or with 
greatest weight in a given field of scientific production.  
Organisation for Economic Co-operation and Develop- 
ment (OECD) Health Division [14], and WHO Depart- 
ment of Health Statistics and Informatics [15]. 
3. RESULTS 
2.2.3. Impact factor 
From 1982 to 2011, we got 669 original Japanese SGA 
papers: 192 were on risperidone, 109 aripiprazole, 106 
olanzapine, 60 perospirone, 58 clozapine, 47 zotepine, 33 
quetiapine, 26 blonanserin, 17 lurasidone, 6 sertindole, 5 
ziprasidone, and 2 paliperidone. We did not find any 
paper on asenapine, iloperidone and amisulpride (pero- 
spirone is only available on the market in Japan, blonan- 
serin is available in Japan and South Korea, and amisul- 
pride is not available in Japan.) 
We used the impact factor (IF) as an indicator of the 
publications’ repercussion. This indicator developed by 
the Institute for Scientific Information (Philadelphia, 
Pennsylvania, USA), is published annually in the Journal 
Citation Reports (JCR) section of the Science Citation 
Index (SCI). We used the IF data of 2011 published in 
the JCR of 2012. 
2.2.4. Participation index As shown in Figure 1, over the last 30 years there had 
a marked increase in the number of SGA papers from 
Japan. The mathematical adjustment to an exponential 
curve permitted us to get a 14.22% of variance unex- 
plained by this fitting, contrariwise, the linear adjustment 
of the measured values gave a percentage of unexplained 
variance of 24.14%, suggesting that the postulated 
Price’s law was fulfilled. Figure 2 depicts the cumula- 
tive growth in total scientific production on SGAs in 
Japan in each five-year period over the previous one. 
Another indicator included in the present analysis is the 
national participation index (PI) of Japan for overall sci- 
entific production (the ratio of the number of documents 
generated by Japan and the total number of documents 
on this topic). This PI has also been compared with 
global PI in biomedical and health sciences (as well as 
for Psychiatry and Neurology area in particular). Like- 
wise, the PI has been correlated with some health data, 
such as total per capita expenditure on health and gross 
domestic expenditure on research and development.  We applied the Bradford’s model to analyse SGA pa- 
pers, and found that the mean number of articles per The PI has also been correlated with the corresponding 
PI for the world’s 15 most productive countries during Bradford zone, without the last zone, whose accuracy 
 
 
Figure 1. Growth of scientific production on second generation antipsychotic drugs (SGAs) in Japan 
and international licensing of different drugs. A linear adjustment of the data was carried out, and a 
fitting to an exponential curve was found, to follow Price’s law of exponential growth for SGA pub-
lication production. Linear adjustment: y = 2.4684x – 16.042 (r2 = 0.7586). Exponential adjustment: 
y = 1.534 e0.1313x (r2 = 0.8578). BD, bipolar disorder. 
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Figure 2. Cumulative growth by five-year periods of scientific production on total Japan productivity 
in biomedicine and health sciences, Psychiatry and Neurology area, and second-generation antipsy-
chotic drugs (SGAs) in Japan. Data from each five-year period are referred to evolution over the pre-
vious period. The period of reference is 1982-1986. Data are expressed in percentages. Notable in 
this respect is the rate of accumulated growth (272.73%) of SGAs in the period 1992-1996. 
 
was obviously lower, being 51.46. The nucleus or first 
zone would be made up exclusively of the Progress in 
Neuro-Psychopharmacology and Biological Psychiatry 
(n = 49) and the second zone of Psychiatry and Clinical 
Neurosciences (n = 43), the official English journal of 
Japanese Society of Psychiatry and Neurology (JSPN). 
The rest of the journals analyzed are included in zones 3 
to 14. A total of 157 different journals were involved in 
those papers. Table 2 lists top 10 most published jour- 
nals which accounted for 40.81% of all the papers in this 
study database. Those journals most extensively used for 
the diffusion of SGA papers have high IFs (7 of them 
have an IF > 3, and 5 an IF > 4). 
Manually classifying articles, we found that 40.06% of 
them belonged to the “experimental pharmacology” group, 
38.10% to the “clinical efficacy” group, 17.17% to the 
“tolerance and safety” group, and 4.67% to the “not spe- 
cified” group (mainly, reviews on different SGAs). 
Figure 3 depicts that the countries generating research 
on SGAs, is the US, whose PI is 32.1, followed by the 
United Kingdom, Germany, Canada, Italy and Spain. But 
if we consider the productivity of these countries in this 
area in relation to their overall production in the field of 
Psychiatry and Neurology, only 4 (Belgium, India, Spain 
and Sweden) of the 15 largest producers in biomedicine 
and health sciences from 1982 to 2011, devote a higher 
percentage of attention to the study of SGAs. Japan oc- 
cupied the last position of these 15 countries. 
Table 2. The 10 journals with highest number of publications 
on second-generation antipsychotic drugs by Japanese authors. 
Journal No. of documents PI IF *
Progress in 
Neuro-Psychopharmacology 






Psychiatry and Clinical  
Neurosciences 
43 6.43 2.133
International Journal of  
Neuropsychopharmacology 
34 5.08 4.578
Psychopharmacology 28 4.19 4.077
European Journal of  
Pharmacology 
28 4.19 2.516




Clinical and Experimental 
21 3.14 2.476
Schizophrenia Research 17 2.54 4.748




PI, participation index; IF, impact factor (2011); *Journal Citation Report, 
2011 (JCR, 2012). 
 
In the analysis of the correlation between PI and the 
per capita health expenditure of each of the countries 
with the highest scientific production in health sciences, 
the distribution obtained is quite similar, except for 
China and India (Figure 4). But Japan occupied the se-  
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Figure 3. Relationship between production of scientific literature on second-generation antipsychotic 
drugs and total production in the field of Psychiatry and Neurology in the world’s 15 most productive 




Figure 4. Relationship between production of scientific literature on second-generation antipsychotic 
drugs and per capita health expenditure and gross domestic expenditure on research and development, in 
the world’s 15 most productive countries in biomedicine and health sciences. PI, participation index; R 
& D, research and development. Total health expenditure per capita personal purchasing power (PPP) 
US $ (data from Organisation for Economic and Co-operative Development (OECD) 2009) [14]. Japan 
and Australia; Data 2008; China and India: Total health expenditure per capita PPP Int $ (data 2008) 
[15]; Gross Domestic Expenditure on R&D (%); Data OECD 2010, except USA and Japan (data 2009), 
Switzerland and The Netherlands (data 2008), China (data 2007) and India (data 2004).  
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venth position in this ranking. 
Top ten most productive institutions in SGA papers 
in Japan were (A) Department of Neuropsychiatry, 
Graduate School of Medicine, Hirosaki Graduate Uni- 
versity, Hirosaki, Aomori Ken (n = 39); (B) University 
of Occupational and Environmental Health, Fukuoka 
(34); (C) Graduate School of Medicine, Hokkaido Uni- 
versity, Sapporo (24); (D) Otsuka Pharmaceutical Co. 
Ltd., Tokushima (24); (E) Department of Psychiatry and 
Neurosciences, Graduate School of Biomedical Sciences, 
Hiroshima University, Hiroshima (17); (F) Osaka Medi- 
cal College, Osaka (16); (G) Dainippon Sumitomo Phar- 
ma Co., Osaka (16); (H) Niigata University Graduate 
School of Medical and Dental Sciences, Niigata (15); (I) 
Keio University School of Medicine, Tokyo (15); and (J) 
Kansai Medical University, Osaka (13). This listing is 
based on the corresponding author’s affiliated institu- 
tions in the AD field in the EMBASE Biomedical Answer 
web database. 
4. DISCUSSION 
The design of this study allows us to make a global as- 
sessment of the growth of scientific SGA literature in 
Japan. The paper number has been through an exponent- 
tial growth over the last 30 years, and especially after 
2000, without evidence of reaching saturation postulated 
by Price’s law [12]. As shown in Figure 1, this date co- 
incides with the approval for marketing by the US Food 
and Drug Administration (FDA) and other international 
regulatory agencies for olanzapine in treating manic epi- 
sodes. Since 2004, other SGAs such as risperidone, que- 
tiapine, ziprasidone, aripiprazole, and asenapine, etc., 
have been also approved for treating manic episodes, and 
olanzapine and aripiprazole for relapse prevention in 
patients with bipolar disorder [16]. Quetiapine is indi- 
cated as monotherapy for the acute treatment of depress- 
sive episodes associated with bipolar disorder, and olan- 
zapine-fluoxetine combination for treating treatment- 
resistant major depressive disorder. Also aripiprazole 
was approved in 2007 by the US FDA for treating treat- 
ment-resistant major depression as an add-on to an anti- 
depressant [16]. Finally, SGAs are also commonly used 
(and studied) in many off-label indications, such as sub- 
stance-induced psychosis, agitation symptoms, tics, sub- 
stance abuse disorders, etc.  
Prestigious journals such as Journal of Clinical Psy- 
chiatry (IF = 5.664), Schizophrenia Research (IF = 
4.748), International Journal of Neuropsychopharma- 
cology (IF = 4.578), or Journal of Clinical Psychophar- 
macology (IF = 4.098) publish SGA articles from Japan. 
This fact indicates both clinical and social relevance that 
Japan has acquired in recent years. Among those 10 
journals most widely used by Japanese authors listed in 
Table 2, 7 are in the ranking of the most relevant in the 
field of Psychiatry (IF > 3.00).  
Although there are no specific data on SGAs pub- 
lished in this field, some authors, also applying biblio- 
metric tools, have reported the research activity in the 
field of schizophrenia as superior to that of other fields 
of psychiatry [17]. These authors also suggest that the 
attraction of research on schizophrenia may have been 
positively affected by the clinical perception of the great- 
er seriousness of the illness compared to other psychia- 
tric illnesses. Moreover, Theander and Wetterberg repor- 
ted that the number of references on schizophrenia in 
MEDLINE has followed the general increase of medical 
publications, which accounts for 0.42% compared to the 
total medical literature in the period studied [18]. 
To the PI of the different countries in scientific pro- 
duction on SGAs, the US and the UK, head the ranking 
of producer countries, and generate over one third of 
total scientific production in this field (36.7%). The fact 
that in these two countries are home to the pharmaceuti- 
cal companies responsible for the development of SGAs 
(olanzapine, Eli Lilly; risperidone and paliperidone, Jan- 
ssen Pharmaceutica; quetiapine, AstraZeneca; ziprasi- 
done, Pfizer; aripiprazole, Bristol-Myers Squibb/Otsuka 
Pharmaceutical) may help explain this high PI. But 
strikingly, Japan is ranked as the sixth producer in this 
field, despite being responsible for the development of 
five SGAs (zotepine, perospirone, aripiprazole, blonan- 
serin, and lurasidone) and the great importance of mental 
health, particularly in the area of schizophrenia. Japan 
was the first and the only Asian country in 2002 to re- 
name schizophrenia into togo-shicchou-sho, in attempt to 
de-stigmatize those with this disorder [6]. This kind of 
effort made by the psychiatrists and lay public in Japan is 
not seen elsewhere in the world. 
Figure 3 shows how some countries, such as Belgium, 
India, or Spain, sit near the top of the ranking for SGA 
paper production with respect its general productivity in 
the Psychiatry & Neurology discipline, reflecting the 
special interest of these countries in SGA research. In a 
similar study, Taiwan which has only about one-fifth (23 
million) of the population of Japan, had produced 359 
papers from 1993 to 2011, being published in compara- 
bly prestigious journals [11]. Contrariwise, the lower 
relative interest in these drugs of countries such as Fran- 
ce, the UK, Switzerland, and specially Japan (Figure 3).  
We would like to offer three reasons for Japanese pro- 
ductivity SGA publications as shown in Figure 3. First, 
the reason can be illustrated in a historical case story of 
carbamazepine [19]. Takezaki and Hanaoka of Totorri 
prefecture in 1971 were the first two psychiatrists in the 
world to discover the use of carbamazapine in treating 
manic patients, but it took a long time to spread this sci- 
entific contribution outside of Japan because the original 
article was published in Senshin Igaku (Folio) [20]. 
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Second, another reason could have been the delay in Ja- 
pan of licensing new drugs or new indications [21], es- 
pecially in neulological [22] and psychiatric [23] medi- 
cations. Apart from sildenafil, Japanese regulatory pro- 
cess was notoriously slow. For example, the first selec- 
tive serotonin reuptake inhibitor (SSRI), fluvoxamine, 
was marketed in Japan in 1999, and second SSRI, par- 
oxetine, in 2001 [23,24]. Japanese regulatory authority 
released the marketing licence of clozapine in 2009, and 
authorized olanzapine and aripiprazole for the indication 
to treat acute mania in 2012 [23]. Shimazawa et al. found 
that of the 23 psychiatric drugs being all approved in the 
UK and the USA, only 13 of them were introduced in 
Japan between September 2000 and July 2011; that none 
of their development strategies adopted the International 
Conference on Harmonisation E5 guideline on simulta- 
neous development of drugs on a global scale; and that 
the median review time (from approval application to 
approval) of these studied 13 drugs in Japan was 23 
months which was considerably longer than those of 
European Medicines Agency and the US FDA (13.5 and 
10.0 months, respectively) [23]. They further lamented 
that the 10 - 13 months difference in review time can not 
explain the overall 87- and 51-month delay in Japan after 
approval in the UK or in the USA [23]. Usually, the pa- 
tients in South Korea and Taiwan can get the needed 
SGAs for their patients in 2 - 3 years following the ap- 
proval of the US FDA. But the improvement of this de- 
lay of an SGA would be improved as evidence of the 
amount of newly published papers from the manufactur- 
ers of aripiprazole and lurasidone. And third, Japan had 
produced higher percentage of SGA papers in basic 
research (40.06%) than clinical papers (38.30%) com- 
paring with other countries/areas in the area such as 
Taiwan (29.53% and 40.11%, respectively) [11]. The 
productiveity of basic research by Japanese psychiatrists 
has always been admired by counterparts in Asian coun- 
tries. But executing clinical drug trials and implementing 
institutional review board for protecting human research 
subjects in Japan have recently become popular. These 
phenomena indicate that remarkable improvement in the 
productivity of clinical research papers in Japan would 
be expected in the near future. 
The correlation of scientific production in SGAs with 
the per capita health expenditure of each country (Fig- 
ure 4), offers us a parallel view of this phenomenon; in 
general, there is confirmation of the notion that the 
higher the spending on health, the greater the research 
production. It is striking, however, to observe the low 
ratios of countries such as Switzerland, Sweden or Neth- 
erlands. The correlation analysis between scientific pro- 
duction in SGAs and the gross domestic expenditure on 
R & D located to Japan at the eleventh position.  
We have offered a picture of the representativeness 
and evolution of international research on SGAs in Japan, 
observing the parameters of quality and dissemination 
most commonly used at an international level. Besides 
the differences in antipsychotic prescribing patterns be- 
tween Japan and other countries [25,26], we also found 
in this study that the research paper productivity on 
SGAs was different from Japan to other Asian coun- 
tries/areas such as Taiwan [11]. But we trust that re- 
search in this field will possibly continue to grow in the 
coming years, bearing in mind that the ideal antipsy- 
chotic drug has not yet been found [5] and that etiopa- 
thogeny of schizophrenia is still mostly unknown.  
4.1. Limitations 
First, we might have excluded those papers on SGAs if 
the authors have not put our study inclusion descriptors 
in the titles or as key words. Moreover, local journals 
that are not indexed in MEDLINE and Excerpta Medica 
during the study period, and those contributions from Ja- 
panese investigators at scientific conferences and meet- 
ings were also not included in our current study.  
Second, in the AD section using the descriptor “Ja- 
pan,” we included those papers with authors specifying 
“Japan” in their addresses only. We did not count those 
papers as Japan papers if the contributor authors from 
Japan had not put their Japanese addresses.  
Third, the use of the SCI impact factor to determine 
the merit or quality of scientific contributions is still de- 
batable. The citation count applied in calculating the im- 
pact factor may not directly reflect the importance or 
quality of one study; on the contrary, it may only repre- 
sent the topic of a given study being “more fashionable”, 
or even “not yet mature” and/or “in need of more stud- 
ies.” This might explain why most universities of the US, 
unlike those in Europe and in Asia, do not usually use 
impact factor to evaluate the academic outputs of their 
faculty members. 
5. CONCLUSION 
The SGA publications in Japan have been through expo- 
nential growth over the studied period, without evidence 
of reaching a saturation point. 
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